Literature DB >> 15095313

Hyperparathyroidism and subsequent incidence of breast cancer.

Karin B Michels1, Fei Xue, Lena Brandt, Anders Ekbom.   

Abstract

Preliminary data are available on the coexistence of primary hyperparathyroidism and breast carcinoma. To further understand the association between hyperparathyroidism and breast cancer, we conducted a record-linkage study in Sweden using the Swedish Cancer Registry from 1958-1997. A total of 9,835 women who underwent surgery for primary parathyroid adenoma were followed to evaluate the hypothesis that a history of primary hyperparathyroidism increases the risk of subsequent breast cancer. During 99,929 person-years of follow-up, 331 cases of newly diagnosed breast cancer were reported. The number of expected breast cancers in this population was 260.0. This resulted in a standardized incidence ratio of 1.27 (95% confidence interval [CI] = 1.14-1.41). The relation persisted over time after the surgical removal of the parathyroid adenoma. Possible explanations for the observed association are a shared etiology including genetic and environmental factors such as early life radiation, and hypercalcemia after the overproduction of parathyroid hormone, which may increase breast cancer incidence. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2004        PMID: 15095313     DOI: 10.1002/ijc.20155

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  16 in total

1.  Hypercalcemia in metastatic breast cancer unrelated to skeletal metastasis.

Authors:  Heather Sigvaldason; Adebola Obayan; Ken von Kuster; K Alok Pathak
Journal:  CMAJ       Date:  2015-10-26       Impact factor: 8.262

2.  Hypercalcaemia in cancer.

Authors:  Simon Conroy; Brendan O'Malley
Journal:  BMJ       Date:  2005-10-22

3.  Primary hyperparathyroidism in prostate cancer: guilty or not guilty?

Authors:  G Mazziotti; S Frara; A Mosca
Journal:  Endocrine       Date:  2018-05-30       Impact factor: 3.633

4.  Uncommon cause of hypercalcaemia in metastatic breast carcinoma.

Authors:  Rohit Barnabas; Ashish Singh; Mazhuvanchary Jacob Paul; Thomas Vizhalil Paul
Journal:  BMJ Case Rep       Date:  2018-02-22

5.  Prevention of breast cancer skeletal metastases with parathyroid hormone.

Authors:  Srilatha Swami; Joshua Johnson; Lance A Bettinson; Takaharu Kimura; Hui Zhu; Megan A Albertelli; Rachelle W Johnson; Joy Y Wu
Journal:  JCI Insight       Date:  2017-09-07

6.  Is the risk of primary hyperparathyroidism increased in patients with untreated breast cancer?

Authors:  V Belardi; E Fiore; E Giustarini; I Muller; S Sabatini; V Rosellini; E Seregni; R Agresti; C Marcocci; P Vitti; C Giani
Journal:  J Endocrinol Invest       Date:  2012-08-29       Impact factor: 4.256

7.  Hypercalcaemia in breast cancer patients: not always bony metastases.

Authors:  Sophie H A Summers; Fung Joon Foo; Sadagopan Varadarajan
Journal:  BMJ Case Rep       Date:  2009-06-01

8.  Risk factors and causes of death in MEN1 disease. A GTE (Groupe d'Etude des Tumeurs Endocrines) cohort study among 758 patients.

Authors:  Pierre Goudet; Arnaud Murat; Christine Binquet; Christine Cardot-Bauters; Annie Costa; Philippe Ruszniewski; Patricia Niccoli; Fabrice Ménégaux; Georges Chabrier; Françoise Borson-Chazot; Antoine Tabarin; Philippe Bouchard; Brigitte Delemer; Alfred Beckers; Claire Bonithon-Kopp
Journal:  World J Surg       Date:  2010-02       Impact factor: 3.352

Review 9.  Nontraditional manifestations of primary hyperparathyroidism.

Authors:  Marcella Donovan Walker; Mishaela Rubin; Shonni J Silverberg
Journal:  J Clin Densitom       Date:  2013 Jan-Mar       Impact factor: 2.617

10.  In serum, higher parathyroid hormone but not lower vitamin D is associated with oral squamous cell carcinoma.

Authors:  H Zhang; H Lu; C Shrestha; Y Feng; Y Li; J Peng; Y Li; Z Xie
Journal:  Curr Oncol       Date:  2015-08       Impact factor: 3.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.